Pharma Mar获得爵士制药5000万美元用于Zepzelca与Atezolizumab联合治疗的FDA批准

投资观察
Oct 15

10月15日 - Pharma Mar SA公告:*公司获得爵士制药5000万美元用于FDA批准*此款项与Zepzelca(Lurbinectedin)与Atezolizumab(Tecentriq)联合治疗成人广泛期小细胞肺癌的完全FDA批准相关。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10